Stocksigma LogoStocksigma Logo

Vista Pharmaceuticals Reports Widened Q3FY26 Loss on Higher Expenses

Vista Pharmaceuticals reported a widened net loss of ₹231.94 lakh for Q3FY26 ended 31 Dec'25, compared to a loss of ₹132.23 lakh YoY

Vista Pharmaceuticals Reports Widened Q3FY26 Loss on Higher Expenses

Vista Pharmaceuticals Ltd · Financial Result · 13 Feb 2026, 8:53 pm

Vista Pharmaceuticals Reports Widened Q3FY26 Loss on Higher Expenses Vista Pharmaceuticals reported a widened net loss of ₹231.94 lakh for Q3FY26 ended 31 Dec'25, compared to a loss of ₹132.23 lakh YoY. Revenue from operations declined 5.4% YoY to ₹241.82 lakh. The loss before tax increased to ₹328.04 lakh from ₹180.44 lakh YoY, driven by higher material and other expenses. The company also recognized an Expected Credit Loss provision of ₹205.43 lakh against trade receivables. Basic EPS for the quarter stood at ₹(0.41), deteriorating from ₹(0.07) in the prior-year period.

Original exchange filing (PDF)

More announcements from Vista Pharmaceuticals Ltd

All Vista Pharmaceuticals Ltd announcements